Publications by authors named "Darren E Ferguson"
Article Synopsis
- Antibody therapy requires careful balance of factors like binding affinity, biophysical traits, and immunogenicity risk to be effective.
- High concentrations (>150 mg/ml) of antibodies are needed for subcutaneous dosing, but high viscosity at those concentrations can complicate delivery and manufacturing.
- This study successfully optimized an anti-PDGF-BB antibody to increase its concentration from 80 mg/ml to over 160 mg/ml while keeping its binding affinity intact, by adjusting its surface charge properties and analyzing 40 unique variants for viscosity.
Advancement in high-throughput screening methods of novel therapeutic proteins for early stage research and development, specifically mAbs, have given mid-scale (milligram to gram scale) purification groups access to more of these molecules. The available purification technologies built to support mid-scale production was not efficient or versatile enough to keep up with this surge. To remedy this problem, we have designed and built a custom instrument using an ÄKTA Pure.
View Article and Find Full Text PDF